Author reply 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer

Intern Med J. 2016 Apr;46(4):507-8. doi: 10.1111/imj.13035.

Authors

A J Lomax¹, P Parente^{1

2}, C Gilfillan^{2

3}, P M Livingston⁴, I D Davis^{1

2}, C Pezaro^{1

2}

Affiliations

¹ Oncology Unit, Eastern Health, Melbourne, Victoria, Australia.
² Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
³ Endocrinology Unit, Eastern Health, Melbourne, Victoria, Australia.
⁴ Faculty of Health, Deakin University, Melbourne, Victoria, Australia.

PMID: 27062210
DOI: 10.1111/imj.13035

No abstract available

Publication types

Letter
Comment

MeSH terms

Androgen Antagonists
Antineoplastic Agents, Hormonal / therapeutic use*
Humans
Male
Prostatic Neoplasms / drug therapy*

Substances

Androgen Antagonists
Antineoplastic Agents, Hormonal